Skip to main content
. 2019 Nov 5;10(60):6526–6535. doi: 10.18632/oncotarget.27251

Table 3. Treatment-related adverse events occurring in >5% of patients.

Adverse event, n (%) Patients (N = 146)
Fatigue 50 (34.2)
Nausea 43 (29.5)
Hyperglycemia 35 (24.0)
Decreased appetite 34 (23.3)
Diarrhea 33 (22.6)
Aspartate aminotransferase increased 25 (17.1)
Vomiting 23 (15.8)
Depression 22 (15.1)
Alanine aminotransferase increased 21 (14.4)
Anxiety 20 (13.7)
Rash 20 (13.7)
Weight decreased 15 (10.3)
Dysgeusia 11 (7.5)
Dyspepsia 10 (6.8)
Mucosal inflammation 10 (6.8)
Insomnia 9 (6.2)